

RE • WORK

NOVEMBER 18-19, 2025 | BOSTON

AI in Healthcare & Pharma Summit



The Colonnade Hotel

REGISTER NOW

Are You Ready to Explore the Future of AI-Enabled Healthcare and Pharma Innovation?

Join us at the heart of healthcare transformation and be part of the community shaping the future of clinical care, drug development, and patient experience.

The **AI in Healthcare & Pharma Summit 2025** is your opportunity to connect with the leaders, innovators, and practitioners building tomorrow's AI-powered health systems. Whether you're driving digital strategy, overseeing clinical trials, or rethinking patient outcomes, this summit offers invaluable insights from those leading the AI revolution across healthcare, biotech, and life sciences.

Don't miss your chance to learn from experts turning AI into measurable impact—and explore how this technology can unlock smarter, faster, and more equitable healthcare for all.

WHAT'S NEW FOR 2025?

- Discover the latest breakthroughs in GenAI, predictive modeling, and clinical decision support.
- Gain practical strategies to drive AI adoption at scale—without burning out your teams.
- Learn how health systems and pharma are aligning around real-world evidence, data sharing, and AI governance.
- Dive into use cases that bridge research and frontline care—transforming diagnostics, documentation, and drug delivery.
- Explore ethical and regulatory frameworks shaping responsible AI use in regulated healthcare environments.
- Connect with providers, payers, pharma leaders, and innovators who are driving outcomes-focused AI transformation.
- Hear directly from patients, caregivers, and clinical teams using AI in the real world.

AI in Healthcare & Pharma 2025 Key Themes:

- **AI in Clinical Practice:** GenAI, decision support, mental health, remote monitoring, and documentation
- **AI in Drug Development:** Accelerating discovery, optimizing trials, and advancing precision medicine
- **Responsible AI:** Governance, privacy, patient consent, and regulatory readiness
- **Adoption & ROI:** How to scale AI solutions, prove value, and align internal stakeholders
- **Equity & Access:** Ensuring AI supports underserved communities and diverse populations
- **Cross-Sector Collaboration:** Linking payers, providers, and pharma through real-world data and shared strategy

Shuja Mohammed, *Head of Strategic Planning & Operations for AI & Data Science*, **ASTRAZENECA**

Gunasekaran (Guna) Singaravelu, *Associate Director*, **DAIICHI SANKYO**

Wei-Ting Ling, *Associate Director*, **GILEAD SCIENCES**

Matt Dixon, *Cloud Architect*, **NORTHWELL HEALTH**

Carolyn Pfeiffer, *Senior Director, Privacy, AI & Ethics and DSSPE Operations*, **JOHNSON & JOHNSONS**

Amir Tahmasebi, *Director, Computer Vision and NLP, Healthcare*, **BECTON DICKINSON**

Sadiq Y. Patel, *VP of Data Science & AI*, **WAYMARK**

Anemone Kasasbeh, *Lead Data Scientist*, **IPG HEALTH**

Hao Zhang, *Director, Digital Healthcare Innovation*, **mitsubishi tanabe pharma america**

Rahul Kashyap, *Medical Director Research*, **WELLSPAN HEALTH**

Ellie Norris, *Director, D&A Strategy and Technology Partnership/ MRL IT Clinical & Real-World Evidence Generation*, **MERCK**

Lance Bradshaw, *Director of Workforce Transformation*, **INTERMOUNTAIN HEALTH**

AI in Healthcare and Pharma Summit 2025 | Program

Day 1 – November 18

8:00-9:00 AM	<i>Registration & Breakfast Networking</i>	
9:00-9:10 AM	Chairperson Opening Remarks	
9:10-9:40 AM	OPENING KEYNOTE: Reducing Clinical Burden with GenAI – From Documentation to Decision Support at Scale As GenAI tools gain traction, health systems are rethinking how AI can support clinicians, not replace them. <ul style="list-style-type: none">How is GenAI being used to reduce administrative burden in clinical workflows?What are the best practices for deploying AI-driven CDS tools at scale?How can we ensure accuracy, trust, and integration across clinical settings?What are the early measurable impacts on clinician time and patient care?	
9:40-10:10 AM	PANEL: From Silos to Synergy –Achieving Real-World Data Collaboration Across Pharma, Providers & Payers Turning real-world data into real-world impact requires breaking down institutional and regulatory barriers. <ul style="list-style-type: none">What are the critical enablers of cross-sector RWD collaboration?How are organizations aligning governance, privacy, and data access strategies?What shared use cases are driving value across payers, providers, and pharma?How can we standardize and scale collaborative data ecosystems?	
10:10-10:40 AM	USE CASE: Risk-Proof AI – Building Clinically Reliable and Regulatory-Ready Systems Deploying AI in regulated environments requires rigorous validation and auditability. <ul style="list-style-type: none">What does a regulatory-grade AI lifecycle look like in practice?How are leading teams addressing traceability, bias, and explainability?What frameworks support FDA, EMA, and EU AI Act compliance?How can we balance speed of innovation with operational risk mitigation?	
10:40-11:10 AM	<i>Coffee & Networking Break in the Exhibition Area</i>	
	Track A: Healthcare <i>Clinical Innovation, Access & Outcomes</i>	Track B: Pharma <i>Accelerating Drug Development & Personalized Medicine</i>
11:10-11:40 AM	AI for Virtual Care – Triage, Escalation & Access via Telehealth AI is driving the next generation of telehealth—more intelligent, efficient, and inclusive. <ul style="list-style-type: none">How is AI being integrated into telehealth triage and decision-making?What gains have been achieved in access and patient stratification?How are escalation protocols and safety nets embedded into AI design?What are the lessons in serving rural, elderly, and high-risk populations?	Regulating AI in R&D – What You Need to Know for FDA, EMA & EU AI Act Readiness The compliance landscape is evolving fast—particularly for AI in early-stage and clinical research. <ul style="list-style-type: none">What are the latest regulatory shifts impacting AI in drug development?How are teams preparing for audits and ensuring model transparency?What documentation and oversight mechanisms are needed?How does the EU AI Act compare to U.S. and global frameworks?
11:40-12:10 AM	GenAI in Mental Health – Enhancing Access While Managing Ethical Boundaries GenAI offers promise in mental health support—but with sensitive ethical implications.	Applying GenAI in Discovery – What Works in Target Identification Pharma R&D teams are experimenting with GenAI to unlock novel targets—but what actually works? <ul style="list-style-type: none">What are successful approaches to GenAI for target prediction?

	<ul style="list-style-type: none"> Where is GenAI currently being used in mental health triage or companionship? What safeguards are essential for managing hallucination and misuse? How can GenAI improve access without displacing human care? What boundaries should guide deployment in emotionally vulnerable contexts? 	<ul style="list-style-type: none"> Where do these tools outperform traditional methods—or fail? How are teams validating GenAI hypotheses with human-in-the-loop feedback? What infrastructure is needed to scale GenAI across discovery teams? <p>Gunasekaran (Guna) Singaravelu, <i>Associate Director</i>, DAIICHI SANKYO</p>
12:10-12:30 PM	INNOVATION SHOWCASE Join us for the Innovation Showcase, featuring two fast-paced 10-minute presentations that highlight groundbreaking AI applications transforming healthcare and pharma.	INNOVATION SHOWCASE Join us for the Innovation Showcase, featuring two fast-paced 10-minute presentations that highlight groundbreaking AI applications transforming healthcare and pharma.
12:30-1:30 PM	<i>Lunch & Networking in the Exhibition Area</i>	
	Track A: Healthcare <i>Clinical Innovation, Access & Outcomes</i>	Track B: Pharma <i>Accelerating Drug Development & Personalized Medicine</i>
1:30-2:00 PM	The Payer Perspective – AI for Smarter, Fairer Health Insurance Payers are deploying AI to personalize coverage decisions and reduce systemic bias. <ul style="list-style-type: none"> How are AI models being used to support equitable policy and pricing? What are the risks around data bias in underwriting or claims adjudication? How do payers balance automation with regulatory oversight? What opportunities exist for payer-provider collaboration? 	Building the AI Stack in Pharma – Unifying Data, Deployment, and Model Governance Enterprise-scale AI requires infrastructure that scales with science, not against it. <ul style="list-style-type: none"> What defines a modern, production-ready AI stack in pharma? How are data engineering, MLOps, and governance being unified? What trade-offs exist between modular tools and full-stack platforms? How are teams aligning across R&D, regulatory, and commercial?
2:00-2:30 PM	FIRESIDE CHAT: Crafting Personalized Patient Access Pathways with AI Personalized care access is becoming table stakes—and AI is the engine behind it. <ul style="list-style-type: none"> How are AI tools optimizing prior auth, eligibility, and intake? What’s the balance between automation and empathetic patient support? What systems are enabling real-time decisions and navigation? How do you maintain equity when customizing access? <p>Moderator: Matt Dixon, <i>Cloud Architect</i>, NORTHWELL HEALTH</p>	FIRESIDE CHAT: From Discovery to Launch – Enabling Smarter Market Access with AI AI is helping align discovery outputs with patient segmentation, pricing, and launch planning. <ul style="list-style-type: none"> How is AI improving market access predictions and planning? What RWE signals matter most for launch success? How are teams using AI to optimize trial-to-launch transitions? Where are the pitfalls in aligning clinical and commercial data?
2:30-3:00 PM	CASE STUDY: GenAI for EHRs – Navigating Noise, Accuracy, and Integration Hospitals are embracing GenAI—but success depends on precision, not promise. <ul style="list-style-type: none"> How are health systems managing hallucination and overfitting? What integrations with EHRs and clinical workflows are most effective? How are teams measuring usability and clinical trust? What guardrails ensure GenAI improves—not complicates—care? 	CASE STUDY: AI for Smarter Manufacturing – Reducing Risk & Waste AI is making pharma manufacturing more predictive, responsive, and sustainable. <ul style="list-style-type: none"> What use cases are succeeding in quality control and batch prediction? How are digital twins being applied in production? What are the measurable gains in cost, waste, and time? How is AI being validated in GMP environments? <p>Wei-Ting Liu, <i>Associate Director</i>, GILEAD SCIENCES</p>
3:00-3:20 PM	<i>Afternoon Networking Break</i>	
3:20-3:50 PM	EVENING KEYNOTE: AI-Native Precision Medicine – Digital Twins, Biomarkers & Adaptive Therapy Infrastructure Precision medicine is being redefined through AI-enabled platforms and patient models. <ul style="list-style-type: none"> What breakthroughs are we seeing in predictive patient modeling? 	

	<ul style="list-style-type: none"> How are digital twins guiding adaptive treatment plans? What data infrastructure is needed to support this shift? How close are we to routine deployment in real-world care?
3:50-4:20 PM	PANEL: Operationalizing Responsible AI – From Principles to Practice in Regulated Settings Responsible AI is no longer abstract—it's an operational requirement. <ul style="list-style-type: none"> How are teams embedding governance into data and model workflows? What tools are enabling real-time monitoring and oversight? How is responsible AI aligned with global regulatory trends? What does accountability look like in high-risk use cases?
4:20-4:50 PM	CLOSING KEYNOTE: Equitable AI by Design – Bias Mitigation, Representativeness & Algorithmic Auditing Equity must be built into AI—not bolted on after deployment. <ul style="list-style-type: none"> What strategies ensure datasets reflect diverse populations? How are bias audits being standardized and enforced? How can equity align with ROI and regulatory readiness? What lessons from failed deployments can guide inclusive design?
4:50-5:00 PM	Closing Remarks
5:00-6:00 PM	<i>Networking & Drinks Reception in the Exhibition Area</i>
6:00 PM	<i>End of Day 1</i>

AI in Healthcare and Pharma Summit 2025 | Program

Day 2 – November 19

8:30-9:20 AM	<i>Registration & Breakfast Networking</i>
9:20-9:30 AM	Chairperson Opening Remarks
9:30-10:00 AM	OPENING PANEL: RWE at Scale – Powering Outcomes-Based Partnerships Between Pharma and Providers <ul style="list-style-type: none"> How are pharma and providers aligning on outcomes-based agreements using RWE? What infrastructure is required to collect and analyze RWE at scale? What barriers still hinder cross-industry data collaboration?
10:00-10:30 AM	USE CASE: Designing Interoperable AI Systems – Linking EHRs, RWE, and Clinical Research Infrastructure Interoperability remains a critical bottleneck in realizing the full potential of AI in healthcare. This session delves into practical strategies for unifying disparate data systems. <ul style="list-style-type: none"> Frameworks for connecting EHRs with real-world datasets and research platforms How to future-proof your AI systems through modular, interoperable architecture Use cases showing tangible clinical and operational impact
10:30-11:00 AM	<i>Coffee & Networking Break in the Exhibition Area</i>
11:00-11:30 AM	KEYNOTE: The Case for Scalable AI – Aligning Clinical Value, Cost Efficiency, and Executive Buy-In As organizations move beyond experimentation, scaling AI responsibly requires strategic alignment across the C-suite. <ul style="list-style-type: none"> How to quantify and communicate clinical ROI to leadership? Building scalable infrastructure that meets regulatory expectations Strategies for navigating budget constraints and cross-functional resistance
11:30-12:00 AM	Designing for Health Equity – Embedding Representativeness, Transparency & Fairness in AI Models This talk examines what it means to build equitable AI from the ground up—and the risks of failing to do so. <ul style="list-style-type: none"> How to detect and correct bias in AI training data? Incorporating social determinants of health into model design What fairness means in the context of clinical decision support tools
12:00-12:30 PM	CASE STUDY: Scaling Enterprise AI with Compliance – Lessons from AstraZeneca <ul style="list-style-type: none"> Learn governance structures for global AI operations How to balance innovation with risk and compliance?

	<ul style="list-style-type: none"> What worked—and what didn’t—during AstraZeneca’s enterprise rollout. <p>Shuja Mohammed, <i>Head of Strategic Planning & Operations for AI & Data Science</i>, ASTRAZENECA</p>
12:30-1:30 PM	<i>Lunch & Networking in the Exhibition Area</i>
1:30-2:00 PM	<p>The AI-Ready Workforce – Skills, Culture & Collaboration to Deliver AI in Practice</p> <p>Transforming AI from concept to clinical reality demands more than just technical tools—it requires the right people and mindset.</p> <ul style="list-style-type: none"> Lessons on upskilling clinical and operational staff for AI adoption. Discover how to create a culture of innovation and experimentation. How to embed AI fluency across diverse healthcare roles? <p>Lance Bradshaw, <i>Director of Workforce Transformation</i>, INTERMOUNTAIN HEALTH</p>
2:00-2:30 PM	<p>PANEL: Beyond Pilots – Scaling AI Without Clinician Burnout or Operational Bottlenecks</p> <p>Many healthcare AI programs stall after initial pilots. This panel explores how to maintain momentum without overwhelming teams.</p> <ul style="list-style-type: none"> Best practices for integrating AI into clinical workflows Managing cognitive load and alert fatigue in clinicians Organizational change management for AI scale-up <p>Speakers: 1 - Matt Dixon, <i>Cloud Architect</i>, NORTHWELL HEALTH</p>
2:30-3:00 PM	<p>CLOSING KEYNOTE: Future or Fiction? Evaluating Multimodal AI, Agents & Digital Twins for Real-World Readiness</p> <p>A future-focused conversation on what’s real, what’s hype, and what’s worth preparing for now.</p> <ul style="list-style-type: none"> Are multimodal models and digital twins delivering real value today? What are the infrastructure and ethical considerations to scale them? How should healthcare leaders prioritize AI R&D over the next 3 years?
3:00 PM	Closing Remarks
3:10 PM	<i>End of the Summit</i>